Skin temperature can possibly affect the effect of scalp cooling. The primary objective is to search for the possible relation between hair loss and the obtained scalp skin temperature with scalp cooling at a standard temperature.
ID
Bron
Verkorte titel
Aandoening
Temperature, Scalp Cooling, Alopecia, Chemotherapy
Ondersteuning
Onderzoeksproduct en/of interventie
Uitkomstmaten
Primaire uitkomstmaten
Hair loss will be the primary outcome variable. Hair loss will be measured asking the patient whether or not a wig or head cover is required, using the World Health Organisation (WHO) grading system and a visual analogue scale (VAS), making pictures and using a trichometer (a diagnostic instrument for measuring changes in hair quantity (mass, hair diameter and hair density).
Achtergrond van het onderzoek
In cancer patients chemotherapy-induced alopecia remains one of the most frequently encountered side-effects of treatment. Scalp cooling is often an effective method to prevent chemotherapy-induced hair loss. Skin temperature, skin perfusion, drug exposure and scalp cooling time may contribute and have to be taken into account in improving the protocol for scalp cooling during administration of chemotherapy.
The primary objective of this study is to search for the possible relation between hair loss and the obtained scalp skin temperature with cooling at a standard temperature. A secondary objective is to identify a temperature cut-off score under which alopecia can be prevented by scalp cooling.
Doel van het onderzoek
Skin temperature can possibly affect the effect of scalp cooling. The primary objective is to search for the possible relation between hair loss and the obtained scalp skin temperature with scalp cooling at a standard temperature.
Onderzoeksopzet
N/A
Onderzoeksproduct en/of interventie
N/A
Algemeen / deelnemers
Wetenschappers
Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)
1. Patients with breast cancer;
2. Age 18 years or more;
3. Written informed consent;
4. Indication for three to six cycles of intravenous administered 5-Fluorouracil-Epirubicin-Cyclophosphamide (FEC) regimen with an epirubicine dose of 90-100 mg/m2 at 3-weekly intervals or Adriamycin-Cyclophosphamide (AC) (adryamycin at a dose of 60 mg/m2;
5. Subsequent chemotherapy consisting of decetaxel or paclitaxel is allowed after three cycles of FEC or AC.
Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)
1. Clinical signs of scalp metastases;
2. Cold sensitivity;
3. Cold agglutinin disease;
4. Cryoglobulinemia;
5. Cryofibrinogenemia;
6. Cold posttraumatic dystrophy.
Opzet
Deelname
Opgevolgd door onderstaande (mogelijk meer actuele) registratie
Geen registraties gevonden.
Andere (mogelijk minder actuele) registraties in dit register
Geen registraties gevonden.
In overige registers
| Register | ID |
|---|---|
| NTR-new | NL2935 |
| NTR-old | NTR3082 |
| Ander register | METC Noord-Holland : M011-013 |
| ISRCTN | ISRCTN wordt niet meer aangevraagd. |